Rho Bio is a lymphatic medicines company. Recent scientific discoveries have revealed that lymphatic system dysfunction underlies numerous chronic conditions, including neurodegenerative, autoimmune, and ophthalmologic diseases. Despite this growing evidence, there are no approved treatments that activate the lymphatic system.

Our protein therapy is the first to target the specific biologic mechanism that stimulates new lymphatic vessel growth and enhances lymphatic pumping. We're initially focusing on ocular applications before expanding into neurology and rare lymphatic disorders.

With seed funding from Mission BioCapital, we've already achieved significant milestones: nominated lead and backup candidates and completed ocular pharmacokinetic studies in non-human primates. We're currently seeking $1.5 million in additional funding to complete non-GLP toxicology studies, obtain FDA PIND feedback, and finalize cell line development.